肾功能严重受损患者的肾肿瘤消融术:现状

IF 4.7 2区 医学 Q1 ONCOLOGY
Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki
{"title":"肾功能严重受损患者的肾肿瘤消融术:现状","authors":"Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki","doi":"10.1007/s11912-024-01533-6","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>To review the current status of kidney tumor ablation in patients with substantial kidney impairment.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status\",\"authors\":\"Toshihiro Iguchi, Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Hideo Gobara, Motoo Araki, Takao Hiraki\",\"doi\":\"10.1007/s11912-024-01533-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose of review</h3><p>To review the current status of kidney tumor ablation in patients with substantial kidney impairment.</p><h3 data-test=\\\"abstract-sub-heading\\\">Recent findings</h3><p>Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.</p><h3 data-test=\\\"abstract-sub-heading\\\">Summary</h3><p>According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.</p>\",\"PeriodicalId\":10861,\"journal\":{\"name\":\"Current Oncology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Oncology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11912-024-01533-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01533-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

综述目的综述肾功能严重受损患者肾脏肿瘤消融术的现状。最近的研究结果最近关于此类患者肾脏肿瘤消融术的报道寥寥无几。据报道,在接受消融术的患者中,4 期或 5 期慢性肾脏病(CKD)患者的发病率为 2.0%-10%。在 4 期或 5 期慢性肾脏病患者中,局部肿瘤控制率为 88%-100%。消融对 CKD 分期的影响尚不明确,观察到的肾功能恶化与低温消融的影响和晚期 CKD 的自然病程一致。治疗的目标是彻底切除肿瘤和维持肾功能,而消融术可以实现这两个目标。鉴于治疗方案有限,消融术可能会在晚期 CKD 患者的治疗中发挥关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

Ablation of Kidney Tumors in Patients with Substantial Kidney Impairment: Current Status

Purpose of review

To review the current status of kidney tumor ablation in patients with substantial kidney impairment.

Recent findings

Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%–10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%–100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD.

Summary

According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.50
自引率
0.00%
发文量
187
审稿时长
6-12 weeks
期刊介绍: This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信